Skip to search formSkip to main contentSkip to account menu

MenACWY

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Meningococcal vaccineVaccines, Conjugate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Factors influencing adolescents’ uptake of and intention to receive the MenACWY-vaccination in the Netherlands: A Cross-Sectional Study.
Background: The incidence of meningococcal disease serogroup W in the Netherlands has been stable up to 2014; serogroup W has… 
2018
2018
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants: Results of an Open, Randomized Trial
Background: This study evaluated the immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis… 
2018
2018
Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open…
2015
2015
Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine…
Background: We evaluated safety, immunogenicity and antibody persistence of meningococcal serogroups A, C, W and Y tetanus toxoid… 
2015
2015
Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received…
Review
2013
Review
2013
Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review
Introduction: Meningococcal disease poses serious health risks globally. The six Neisseria meningitidis serogroups responsible… 
2012
2012
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
2012
2012
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent menACWY conjugate vaccine formulations
Introduction Meningococcal serogroup C (MenC) conjugate vaccines are used routinely for infant immunisation in Canada and Europe… 
2010
2010
Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined…
ABSTRACT This study evaluated the safety, tolerability, and immunogenicity of an investigational quadrivalent meningococcal… 
2010
2010
530 Persistence of Immune Response to Candidate Meningococcal Serogroups A, C, W-135, Y Tetanus Toxoid-Conjugated Vaccine (MenACWY-TT) up to 42 Months Following Primary Vaccination
Background and aims: A primary dose of the candidate meningococcal A, C, W-135, Y tetanus toxoid-conjugated vaccine (MenACWY-TT… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)